Bryostatin-1: Phase IIb started

Neurotrope began a double-blind, placebo-controlled, U.S. Phase IIb trial to evaluate 10, 20 and 40 ug IV Bryostatin-1 over 24 weeks in about 150 patients. In the first 12-week treatment period, patie...